FDA clears LASIX generics after non-safety withdrawal
Published Date: 8/14/2026
Notice
Summary
The FDA has decided that LASIX tablets (20 mg, 40 mg, and 80 mg) were not taken off the market because of safety or effectiveness problems. This means generic drug makers can keep getting approval to sell their versions of LASIX, helping patients access affordable options without delays. If you use or make these meds, this decision keeps things steady and reliable with no extra costs or interruptions.
Analyzed Economic Effects
2 provisions identified: 1 benefits, 1 costs, 0 mixed.
Generics Can Keep Using LASIX Reference
The FDA determined that LASIX (furosemide) tablets, 20 mg, 40 mg, and 80 mg, were not withdrawn from sale for reasons of safety or effectiveness. Because of this, the FDA will not begin procedures to withdraw approval of abbreviated new drug applications (ANDAs) that refer to these products and will continue to approve ANDAs that refer to them as long as the applications meet legal and regulatory requirements.
Potential Labeling Update Advice for ANDAs
The FDA said that if it determines labeling for LASIX (furosemide) tablets, 20 mg, 40 mg, and 80 mg, should be revised to meet current standards, the Agency will advise ANDA applicants to submit such labeling. ANDA applicants may therefore need to update labeling if FDA later requires it.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
2026-19921, Determination That SULFADIAZINE (Sulfadiazine) Tablet, 500 Milligrams, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness
The FDA has decided that the 500 mg sulfadiazine tablet wasn’t taken off the market because it was unsafe or didn’t work. This means generic drug makers can now apply to sell their versions, as long as they meet all the rules. Patients and pharmacies could see more affordable options soon, with no safety worries holding things back.
2026-19850, Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Submission of Petitions: Food Additive, Color Additive (Including Labeling), Submission of Information to a Master File in Support of Petitions; and Electronic Submission Using Food and Drug Administration Form 3503
The FDA is asking for public feedback on how it collects info about food and color additives, including their labels and safety petitions. This affects companies that want to add or change ingredients in food and how they submit their paperwork electronically. Comments are due by October 29, 2026, and the process helps keep food safe without adding extra costs or delays.
Previous / Next Documents
Previous: 2026-16647, DISA Technologies, Inc.; Environmental Assessment and Finding of No Significant Impact
The Nuclear Regulatory Commission is giving the green light for DISA Technologies to start cleaning up an old uranium mine waste site in Colorado using their special high-pressure slurry method. This means safer land without big environmental problems, and the work could begin soon with no extra costs to the public. Local communities and the environment will benefit from this smart cleanup plan.
Next: 2026-16649, New England Fishery Management Council; Public Meeting
The New England Fishery Management Council is holding a public meeting on August 28, 2026, to discuss fishing rules for shared fish stocks in New England waters. Fishermen, industry advisors, and the public can share their thoughts before the Council decides on new fishing plans. This meeting helps shape policies that could affect fishing limits and the local fishing economy.